Study summary · research use only
Teriparatide
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This is a drug-information summary (human; general clinical description, not an original clinical trial) about teriparatide, a recombinant human parathyroid hormone analogue used to treat osteoporosis in women or men with a high risk for bone fracture. The abstract reports that teriparatide therapy has not been associated with serum aminotransferase elevations during therapy and has not been implicated in instances of clinically apparent liver injury.
Abstract
Teriparatide is a recombinant human parathyroid hormone analogue that is used to treat osteoporosis in women or men with a high risk for bone fracture. Teriparatide therapy has not been associated with serum aminotransferase elevations during therapy and has not been implicated in instances of clinically apparent liver injury.
pepmg summarizes the peer-reviewed literature and links to every source. It sells nothing and ships nothing. Where an FDA label, a peer-reviewed study or a clinical-trial registry entry (labeled trial registry, not peer-reviewed) has published a dose, pepmg reports it with the source named; it gives no personalized recommendations and no administration technique. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.